Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers. The company was founded in 1996 and is based in West Lafayette, Indiana.
Funding Rounds (3) - $49.1MUpdate
Silicon Valley Bank works with technology, life science, cleantech, venture capital, private...
Blue Chip Venture Company is a venture fund focusing on technology companies serving the media...
American Bailey Ventures was added to CrunchBase in 2010
Life Sciences VC
Oldest investment firms
Investing in Biomedical Innovation
3000 Kent Avenue
West Lafayette, IN 47906